AMGN AMGEN Earnings and EPS analysis

?
Relative Growth: Rel. Growth: 83
Relative Strength: Rel. Strength: 79
Relative Valuation: Rel. Valuation: 49
Relative Profitability: Rel. Profitability: 95

EPS in 2026 (TTM): $16.22

Last Report Period Date: Jun 30, 2026

As of August 2026, AMGN's current EPS stands at $16.22, according to the latest financial reports. For the year 2025, the company recorded an earnings per share (EPS) of $14.33, which marks an increase compared to its EPS of $7.62 in 2024. AMGN reported an EPS of $4.4 for the quarterly report ending on Jun 30, 2026.

AMGN earnings history

Historical annual and quarterly earnings per share (EPS) data for AMGEN
EPS (TTM)
$16.22
EPS Growth YoY (Quarterly)
65.4%
EPS (Quarterly)
$4.4
EPS Growth (Quarterly)
30.6%

For 2025, AMGEN's EPS was $14.33, an increase of 88.1% from $7.62 in 2024. For the fiscal quarter that ended on Jun 30, 2026, the per-share earnings was $4.4, showing a 65.4% increase from the same quarter last year. For the twelve months ending June 2026, the EPS is $16.22. For the year 2024, the yearly earnings per share was $7.62, marking a decrease of 39.3% from 2023.

AMGN EPS vs price chart

AMGN EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
65.4%
EPS growth YoY
88.1%
EPS growth 3Y avg
5.6%
EPS growth 5Y avg
2.9%

AMGEN has registered an increase in EPS of 65.4% during the last 12 months (YoY, quarterly). Examining a broader timeline, the company maintained an average EPS growth rate of 5.6% per year for the last three years. AMGEN had an average annual EPS growth rate of 2.9% during the last 5 years. A 10-year view shows that AMGN has seen an average EPS growth of 4.6% per year.

AMGN Earnings Waterfall

Breakdown of revenue, profit and net income for AMGEN

AMGN Earnings vs Peers

What are the earnings of AMGN compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
BMY Bristol-Myers Squibb Company 14.73 178.7% 5.3% N/A
AMGN AMGEN Inc 27.09 88.1% 5.6% 2.9%
JNJ Johnson & Johnson 30.96 90.6% 17.7% 14.8%
PFE Pfizer Inc 36.93 -3.5% -37.4% -3.7%
ABT Abbott Laboratories 37.63 -51.4% -1.8% 8.2%
BIIB Biogen Inc 38.17 -21.2% -25% -18.7%
ILMN Illumina Inc 40.63 171.1% N/A 4.1%
LLY Lilly(Eli) & Company 42.07 95.6% 49.2% 27.5%
ABBV Abbvie Inc 74.64 -1.3% -29.1% -2.8%
GILD Gilead Sciences Inc N/A 1,700% 23.2% 132.8%

All data is based on quarterly TTM periods, unless otherwise specified.